ARCHIVÉ - Relevé des maladies transmissibles au Canada

 

Volume 37 • ACS-7
novembre 2011

Une déclaration d'un comité consultatif (DCC).
Comité consultatif national de l'immunisation (CCNI).

Recommandations relatives à l'utilisation du vaccin antigrippal vivant atténué (FluMist®) : Déclaration complémentaire sur la vaccination antigrippale pour la saison 2011-2012

Liste des abbréviations

att
atténué
ca
adapté au froid
CCNI
Comité consultatif national de l'immunisation
DICT
Dose infectieuse de culture tissulaire                  
EOPS
Exempt d'organismes pathogènes spécifiques
ESG
Effet secondaire grave
ICC
Influenza confirmée par culture
H
Antigène hémagglutinine
IC
Intervalle de confiance
IgG
Immunoglobuline G
IH
Inhibition de l'hémagglutination
ITT
Intention de traiter
ml
Millilitre
MRAIM
Maladie respiratoire aiguë nécessitant une intervention médicale
VRI
Maladie des voies respiratoires inférieures
OMS
Organisation mondiale de la Santé
pp
selon le protocole (population évaluée dans la dernière analyse)
RIMC
Réponse immunitaire à médiation cellulaire
RMTC
Relevé des maladies transmissibles au Canada
RSIM
Respiration sifflante importante du point de vue médical
SGB
Moyenne géométrique du titre
MGT
Tissue-culture infective dose
ts
thermosensible
UFF
Unités de foyers fluorescents
µg
Microgramme
VAF-T
Vaccin antigrippal trivalent adapté au froid (préparation réfrigérée)
VTI
Vaccin antigrippal trivalent inactivé (injectable)
VVAI
Vaccin antigrippal à virus vivant attenué (formulation réfrigérée)

Remerciements

† Cette declaration a été préparée et approuvée par le CCNI.

Members: Dre J. Langley (présidente), Dre B. Warshawsky (vice-présidente), Dr C. Cooper, Dre  N. Crowcroft, Mme A. Hanrahan, Dre B. Henry, Dre D. Kumar, Dre S. McNeil, Dre C. Quach-Thanh, Dr  B. Seifert, Dre D. Skowronski, Dre  Wendy Vaudry, Dr Richard Warrington.

Représentants de liaison : Dr J. Brophy (Association canadienne pour la recherche et l'évaluation en immunisation), Dre A. Mawle (U.S. Center for Disease Control and Prevention), Dre Heather Morrison (Conseil des médecins hygiénistes en chef), Mme  S. Pelletier (Association pour la prévention des infections à l'hôpital et dans la communauté), Dre  A. Opavsky (Association pour la microbiologie médicale et l'infectiologie Canada), Mme  K. Pielak (Coalition canadienne des infirmières et infirmiers pour l'immunisation, Dr  P. Plourde (Comité consultatif de la médecine tropicale et de la médecine des voyages), Dre S. Rechner (Collège des médecins de famille du Canada), Dre M. Salvadori (Société canadienne de pédiatrie), Dre  V. Senikas (Société des obstétriciens et gynécologues du Canada), Dre N. Sicard (Association canadienne de santé publique).

Représentants d'office : Lcol J. Anderson (Dr ) (ministère de la Défense nationale), Dre  Ezzat Farzad (Direction générale de la santé des Premières nations et des Inuits – Bureau de médecine communautaire), Dre A. Klein (Direction des produits biologiques et des thérapies génétiques), Dre  J. Laroche (Centre de l'immunisation et des maladies respiratoires infectieuses), Dre  B. Law (Centre de l'immunisation et des maladies respiratoires infectieuses), Mme  D. Poulin (Centre de l'immunisation et des maladies respiratoires infectieuses), Dr M. Tepper (ministère de la Défense nationale).

Autres membres du Groupe de travail sur l'influenza `: Dr P. Van Buynder, Dre B. Cholin, Dr  G. DeSerres, Dr  I. Gemmill, Dr S. Halperin.

References

  1. AstraZeneca Canada. FLUMIST® : Monographie. Révision. Mississauga: AstraZeneca Canada;2011 [Consultation le 24 mars 2011].
  2. Santé Canada. Sommaire des motifs de décision (SMD) FLUMISTMD. 2011.
  3. Cha TA, Kao K, Zhao J, et coll. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol. 2000;38(2):839-45.
  4. Buonagurio DA, O'Neill RE, Shutyak L, et coll. Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology. 2006;347(2):296-306.
  5. Belshe RB, Mendelman PM, Treanor J, et coll. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998;338(20):1405-12.
  6. Belshe RB, Gruber WC, Mendelman PM, et coll. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136(2):168-75.
  7. Tam JS, Capeding MR, Lum LC, et coll. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J. 2007;26(7):619-28.
  8. Vesikari T, Fleming DM, Aristegui JF, et coll. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics. 2006;118(6):2298-312.
  9. Gaglani MJ, Piedra PA, Herschler GB, et coll. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004;158(1):65-73.
  10. Halloran ME, Piedra PA, Longini IM, Jr., et coll. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007;25(20):4038-45.
  11. Bracco Neto H, Farhat CK, Tregnaghi MW, et coll. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J. 2009;28(5):365-71.
  12. Lum LCS, Borja-Tabora CF, Breiman RF, et coll. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine. 2010;28(6):1566-74.
  13. Rhorer J, Ambrose CS, Dickinson S, et coll. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine. 2009;27(7):1101-10.
  14. Glezen WP, Gaglani MJ, Kozinetz CA, et coll. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis. 2010;202(11):1626-33.
  15. Grijalva CG, Zhu Y, Griffin MR. Evidence of effectiveness from a large county-wide school-based influenza immunization campaign. Vaccine. 2009;27(20):2633-6.
  16. Piedra PA, Gaglani MJ, Kozinetz CA, et coll. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005;23(13):1540-8.
  17. Piedra PA, Gaglani MJ, Kozinetz CA, et coll. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007;120(3):e553-64.
  18. King JC, Jr., Stoddard JJ, Gaglani MJ, et coll. Effectiveness of school-based influenza vaccination. N Engl J Med. 2006;355(24):2523-32.
  19. Belshe RB, Edwards KM, Vesikari T, et coll. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7):685-96.
  20. Ashkenazi S, Vertruyen A, Aristegui J, et coll. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25(10):870-9.
  21. Fleming DM, Crovari P, Wahn U, et coll. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25(10):860-9.
  22. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza other respi viruses. 2011;5(2):67-75.
  23. Belshe R, Edwards K, Vesikari T, et coll. Live attenuated versus inactivated influenza vaccine in infants and young children (supplementary appendix). N Engl J Med. 2007;356(7).
  24. Belshe RB, Toback SL, Yi T, et coll. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza other respi viruses. 2010;4(3):141-5.
  25. Block SL, Heikkinen T, Toback SL, et coll. The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J. 2011;30(3):203-7.
  26. Nichol KL, Mendelman PM, Mallon KP, et coll. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999;282(2):137-44.
  27. Edwards KM, Dupont WD, Westrich MK, et coll. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis. 1994;169(1):68-76.
  28. Monto AS, Ohmit SE, Petrie JG, et coll. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009;361(13):1260-7.
  29. Wang Z, Tobler S, Roayaei J, et coll. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA. 2009;301(9):945-53.
  30. Treanor JJ, Kotloff K, Betts RF, et coll. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine. 1999;18(9-10):899-906.
  31. Ohmit S, Victor J, Rotthoff J, et coll. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006;355(24):2513-22.
  32. Ohmit S, Victor J, Teich E, et coll. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis. 2008;198(3):312-7.
  33. Bernstein DI, Yan L, Treanor J, et coll. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J. 2003;22(1):28-34.
  34. Lee MS, Mahmood K, Adhikary L, et coll. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J. 2004;23(9):852-6.
  35. Block SL, Reisinger KS, Hultquist M, et coll. Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects. Antimicrob Agents Chemother. 2007;51(11):4001-8.
  36. Eick AA, Wang Z, Hughes H, et coll. Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine. 2009;27(27):3568-75.
  37. Ambrose CS, Walker RE, Connor EM. Live attenuated influenza vaccine in children. Semin Pediatr Infect Dis. 2006;17(4):206-12.
  38. Boyce TG, Gruber WC, Coleman-Dockery SD, et coll. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine. 1999;18(1-2):82-8.
  39. Belshe RB, Gruber WC, Mendelman PM, et coll. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis. 2000;181(3):1133-7.
  40. King JC, Jr., Lagos R, Bernstein DI, et coll. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis. 1998;177(5):1394-7.
  41. Zangwill KM, Droge J, Mendelman P, et coll. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J. 2001;20(8):740-6.
  42. Nolan T, Lee MS, Cordova JM, et coll. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine. 2003;21(11-12):1224-31.
  43. Sasaki S, Jaimes MC, Holmes TH, et coll. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol. 2007;81(1):215-28.
  44. Weinberg A, Song LY, Walker R, et coll. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr. 2010;55(2):189-96.
  45. Schiff GM, Linnemann CC, Jr., shea L, et coll. Evaluation of a live, attenuated recombinant influenza vaccine in high school children. Infect Immun. 1975;11(4):754-7.
  46. Rudenko LG, Lonskaya NI, Klimov AI, et coll. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds. Bull World Health Organ. 1996;74(1):77-84.
  47. Belshe RB, Swierkosz EM, Anderson EL, et coll. Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine. J Infect Dis. 1992;165(4):727-32.
  48. Mallory RM, Malkin E, Ambrose CS, et coll. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS ONE. 2010;5(10):e13755.
  49. Nolan T, Bernstein DI, Block SL, et coll. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics. 2008;121(3):508-16.
  50. Breiman RF, Brooks WA, Goswami D, et coll. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine. 2009;27(40):5472-9.
  51. Ambrose CS, Wu X, Welshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J. 2010;29(9):806-11.
  52. Belshe R, Lee MS, Walker RE, et coll. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines. 2004;3(6):643-54.
  53. Izurieta HS, Haber P, Wise RP, et coll. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA. 2005;294(21):2720-5.
  54. Vasu N, Ghaffari G, Craig ET, et coll. Adverse events associated with intranasal influenza vaccine in the United States. Ther Adv Respir Dis. 2008;2(4):193-8.
  55. Haber P, Arana J, Walton K. Safety of live attenuated influenza vaccine in children aged 24-59 months, Vaccine Adverse Event Reporting System (VAERS), 2007-2009. 49th Interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA. September 12-14, 2009. Abstract GI-872. 2009.
  56. Toback SL, Baxter R, Sifakis F, et coll. A post-licensure evaluation of the safety of Live Attenuated Influenza Vaccine in individuals 5-49 years of age. 2011.
  57. Forrest BD, Pride MW, Dunning AJ, et coll. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol. 2008;15(7):1042-53.
  58. Mendelman PM, Cordova J, Cho I. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine. 2001;19(17-19):2221-6.
  59. McKeith D, Bodalia B, Pejcz J, et coll. A Phase II, prospective, randomized, double-blind, placebo-controlled trial to assess the safety and tolerability of influenza virus vaccine, trivalent, types A & B live cold adapted liquid formulation (CAIV-T) in healthy children and adolescents ages 6 to 18 years (unpublished data). [In press].
  60. Bergen R, Black S, Shinefield H, et coll. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J. 2004;23(2):138-44.
  61. Piedra PA, Gaglani MJ, Riggs M, et coll. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005;116(3):e397-407.
  62. Storms WW, Dick EC, Busse WW. Intranasal immunization with attenuated live influenza vaccine in asthma. J Allergy Clin Immunol. 1976;58(2):284-90.
  63. Redding G, Walker RE, Hessel C, et coll. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2002;21(1):44-8.
  64. Gaglani MJ, Piedra PA, Riggs M, et coll. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008;27(5):444-52.
  65. Gorse GJ, O'Connor TZ, Young SL, et coll. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine. 2003;21(17-18):2133-44.
  66. Forrest BD, Steele AD, Hiemstra L, et coll. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine. 2011;29(20):3633-9.
  67. De Villiers PJT, Steele AD, Hiemstra LA, et coll. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine. 2009;28(1):228-34.
  68. Treanor JJ, Mattison HR, Dumyati G, et coll. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med. 1992;117(8):625-33.
  69. Jackson LA, Holmes SJ, Mendelman PM, et coll. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine. 1999;17(15-16):1905-9.
  70. Tennis P, Toback SL, Andrews E, et coll. A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. Vaccine. 2011;29(31):4947-52.
  71. Moro PL, Broder K, Zheteyeva Y, et coll. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol. 2011;204(2):146.e1-146.e7.
  72. King JC, Jr., Treanor J, Fast PE, et coll. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis. 2000;181(2):725-8.
  73. King JC, Jr., Fast PE, Zangwill KM, et coll. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J. 2001;20(12):1124-31.
  74. Levin MJ, Song LY, Fenton T, et coll. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine. 2008;26(33):4210-7.
  75. Halasa N, Englund JA, Nachman S, et coll. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine. 2011;29(24):4110-5.
  76. Fiore AE, Uyeki TM, Broder K, et coll. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
  77. Mallory RM, Yi T, Ambrose CS. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age. Vaccine. 2011;29(26):4322-7.
  78. Block SL, Yogev R, Hayden FG, et coll. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine. 2008;26(38):4940-6.
  79. Talbot TR, Crocker DD, Peters J, et coll. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol. 2005;26(5):494-500.
  80. Vesikari T, Karvonen A, Korhonen T, et coll. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J. 2006;25(7):590-5.
  81. Ali T, Scott N, Kallas W, et coll. Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist). Clin Infect Dis. 2004;38(5):760-2.
  82. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 2002;15(2):295-323.
  83. Jackson LA, Neuzil KM, Baggs J, et coll. Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study. Pediatrics. 2006;118(5):2032-7.
  84. Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol. 2007; 28(6):702‑7.

Détails de la page

Date de modification :